Suppr超能文献

miR-135b 通过下调 FZD1 逆转非小细胞肺癌细胞的化疗耐药性。

miR-135b reverses chemoresistance of non-small cell lung cancer cells by downregulation of FZD1.

机构信息

Department of Oncology, Affiliated Hospital of Guangdong Medical College, 57 Renmin Road, Zhanjiang, PR China.

Department of Oncology, Zhanjinag Central People's Hospital, 2 Cunjin Road, Zhanjiang, Guangdong, PR China.

出版信息

Biomed Pharmacother. 2016 Dec;84:123-129. doi: 10.1016/j.biopha.2016.09.027. Epub 2016 Sep 16.

Abstract

BACKGROUND

Non-small cell lung cancer (NSCLC) chemoresistance usually limits the clinical efficacy of chemotherapeutic approaches. However, few reports have revealed the regulation of miR-135b and Frizzled-1 (FZD1) involved in NSCLC chemoresistance.

METHODS

To identify the mechanism of miR-135b and FZD1 in NSCLC chemoresistance and to observe their biological functions, we detected the expression levels of miR-135b and FZD1 by conducting quantitative real-time polymerase chain reaction (RT-qPCR) and modified the expressions of miR-135b and FZD1 by transiently transfecting cells with miR-135b mimics or FZD1-siRNA. The 3'-untranslated region (3'-UTR) of FZD1 combined with miR-135b was verified through dual-luciferase reporter assay.

RESULTS

Compared with that in A549 parental cell lines, the miR-135b expression in drug-resistant lung cancer cell lines (A549/DDP) was decreased and their FZD1 expression was increased. The increased miR-135b expression and silenced FZD1 expression enhanced the sensitivity of resistant cells to cisplatin treatment. The high expression of miR-135b in A549/DDP cells remarkably decreased the mRNA levels of FZD1. FZD1 was further identified as the functional downstream target of miR-135b by directly targeting the 3'-UTR of FZD1.

CONCLUSION

The amplification of miR-135b suppressed NSCLC chemoresistance by directly mediating the FZD1 downregulation.

摘要

背景

非小细胞肺癌(NSCLC)的化疗耐药性通常限制了化疗方法的临床疗效。然而,鲜有报道揭示了 miR-135b 和卷曲蛋白 1(FZD1)在 NSCLC 化疗耐药性中的调节作用。

方法

为了确定 miR-135b 和 FZD1 在 NSCLC 化疗耐药性中的作用机制并观察它们的生物学功能,我们通过定量实时聚合酶链反应(RT-qPCR)检测 miR-135b 和 FZD1 的表达水平,并通过瞬时转染 miR-135b 模拟物或 FZD1-siRNA 来改变 miR-135b 和 FZD1 的表达。通过双荧光素酶报告基因检测验证 FZD1 的 3'-非翻译区(3'-UTR)与 miR-135b 结合。

结果

与亲本细胞系 A549 相比,耐药肺癌细胞系(A549/DDP)中的 miR-135b 表达降低,而 FZD1 表达升高。增加 miR-135b 表达和沉默 FZD1 表达可增强耐药细胞对顺铂治疗的敏感性。A549/DDP 细胞中高表达的 miR-135b 显著降低了 FZD1 的 mRNA 水平。通过直接靶向 FZD1 的 3'-UTR,FZD1 被进一步鉴定为 miR-135b 的功能性下游靶标。

结论

miR-135b 的扩增通过直接介导 FZD1 的下调抑制 NSCLC 化疗耐药性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验